Siltuximab Matching Placebo
Phase 2
Siltuximab Matching Placebo is one of 3 therapeutic programs targeting Schwannomatosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Schwannomatosis
#DrugCompanyPhaseTrials
1Aimovig
AmgenPhase 2
Sylvant
RRECORDATI GROUP
Phase 2
Siltuximab Matching Placebo
MMassachusetts General Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Siltuximab Matching Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital